Dr. David A. Liebner, MD
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Medical school
- State University of New York at Buffalo School of Medicine (2007)
- Years since graduation
- 19
- In the NPI registry since
- 2009
- Medicare patients seen, 2024
- 99
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2007Medical school: State University of New York at Buffalo School of Medicine
- 2009Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
OH license 35.095613
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Ohio State University State Health System Columbus, OH
Medical groups
- Osu Internal Medicine LLC (1,161 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 99
- Services billed
- 302
- Patients’ average age
- 70
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 196 | 60 |
| Established patient office or other outpatient visit, 30-39 minutes | 40 | 29 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 36 | 11 |
| New patient office or other outpatient visit, 60-74 minutes | 21 | 21 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Sorafenib (sorafenib tosylate) | 18 |
| Pazopanib Hcl | 17 |
| Levothyroxine Sodium Other prescribers in Columbus, OH | 16 |
| Ogsiveo (nirogacestat hydrobromide) | 15 |
| Dexamethasone Other prescribers in Columbus, OH | 15 |
| Verzenio (abemaciclib) | 15 |
| Eliquis (apixaban) Other prescribers in Columbus, OH | 13 |
| Ondansetron Hcl Other prescribers in Columbus, OH | 13 |
| Alecensa (alectinib hcl) | 11 |
| Votrient (pazopanib hcl) | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $1,170 in total to this clinician.
| Deciphera Pharmaceuticals Inc. | $1,170 |
|---|
| Honoraria | $1,170 |
|---|
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Deciphera Pharmaceuticals Inc. Mar 17, 2025 | Honoraria VIMSELTINIB · ONCOLOGY | $1,170 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $41,591 in research payments for these studies, mostly to the institutions running them.
- Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma
Epizyme, Inc. · Terminated · NCT04204941 - Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, Alone or in Combination With Other Agents, in HLA-A2+ Participants With NY-ESO-1 and/or LAGE-1a P…
Adaptimmune LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.